Skip to content
    Intuitive Surgical logo

    Intuitive Surgical

    www.intuitive.com

    Intuitive Surgical is a Series A to Series C stage investment firm. It has made 13 investments. 60% of their portfolio is in Healthcare. Deal activity decreased year-over-year (2 deals in the last 12 months vs 3 prior). Average disclosed round size is $89.4M (across 14 rounds with reported amounts).

    Find people at Intuitive Surgical on Goldilocks AI

    Portfolio

    13

    Fund Size

    —

    Top Stage

    Series C

    Last 12 Mo

    2

    Team

    Craig H. Barratt, PhD

    Craig H. Barratt, PhD

    Lead Independent Director, Intuitive

    Anthony McGrogan

    Anthony McGrogan

    Vice President and General Manager, Single-Port Platform

    Bill Maisel, MD, MPH

    Bill Maisel, MD, MPH

    Senior Vice President, Regulatory Affairs and Quality Assurance (RAQA)

    Chris Carlson, PhD

    Chris Carlson, PhD

    Executive Vice President, Research, Corporate Development, Corporate Strategy, and Intuitive Ventures

    Dirk Barten

    Dirk Barten

    Commercial President, Senior Vice President, Europe

    Federico Barbagli, PhD

    Federico Barbagli, PhD

    Senior Vice President and General Manager, Endoluminal

    Glenn Vavoso

    Glenn Vavoso

    Commercial President, Senior Vice President, Asia Pacific

    Iman Jeddi, PhD

    Iman Jeddi, PhD

    Senior Vice President and General Manager, da Vinci Platforms & Product Operations

    Jason Hart

    Jason Hart

    Senior Vice President, Global Marketing

    Sreelakshmi Kolli

    Sreelakshmi Kolli

    Align Technology, Inc., Executive Vice President, Chief Product and Digital Officer

    Stephen Thompson

    Stephen Thompson

    Vice President and General Manager, Worldwide Indirect

    Todd Robin

    Todd Robin

    Vice President and General Manager, Global Services

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    15 investments
    CompanyRoundAmountDate
    Galvanize logoGalvanizeBridge—Sep 2025
    Galvanize Therapeutics logoGalvanize TherapeuticsSeries C$100MSep 2025
    OrganOx logoOrganOxGrowth$160MMay 2025
    VAHATICOR logoVAHATICORSeries B$23MJan 2025
    Apreo Health logoApreo HealthSeries B$130MJan 2025
    CCapstan MedicalSeries C$110MDec 2024
    Capstan logoCapstanSeries C$110MDec 2024
    Amber Therapeutics logoAmber TherapeuticsSeries A$100MJun 2024
    Neocis logoNeocisUnknown$20MJan 2024
    Cellares logoCellaresSeries C$255MAug 2023
    Capstan logoCapstanSeries B$175MJan 2023
    Medcrypt logoMedcryptSeries B$25MNov 2022
    Optellum logoOptellumSeries A$14MSep 2022
    Optellum logoOptellumSeries A$14MJan 2022
    Broncus logoBroncusSeries A$15MJan 2018

    Top Co-Investors

    Intuitive Ventures11 shared
    Eclipse4 shared
    Norwest Venture Partners4 shared
    Sofinnova Partners3 shared
    Yu Galaxy2 shared
    Fidelity Management & Research Company2 shared
    Elevage Medical Technologies2 shared
    Apple Tree Partners2 shared
    Gilmartin Capital2 shared
    Perceptive Xontogeny Venture Fund2 shared
    Ally Bridge Group2 shared
    T. Rowe Price2 shared
    Perceptive Advisors2 shared
    8VC2 shared
    DFJ Growth2 shared
    Bristol Myers Squibb2 shared
    Mercia Asset Management2 shared
    F-Prime Capital2 shared
    Lightstone Ventures2 shared
    Cormorant Asset Management1 shared

    Last updated: 7 October 2026